Zoetis' (ZTS) Simparica Should Gain Approval in March - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Zoetis (ZTS) Tops Q4 EPS by 4c; Affirms FY16 EPS Guidance
February 16, 2016 7:02 AM ESTZoetis (NYSE: ZTS) reported Q4 EPS of $0.43, $0.04 better than the analyst estimate of $0.39. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.25 billion.
GUIDANCE:
Zoetis sees FY2016 EPS of $1.71-$1.81, versus the consensus of $1.81. Zoetis sees FY2016 revenue of $4.65-4.775 billion, versus the consensus of $4.82 billion.
In 2015, Zoetis continued to affirm our reputation as the global leader in the animal health industry with a strong financial performance, ongoing investments in... More
